We report a digoxin radioimmunoassay in human urine employing commercially available reagents. The calibration curve has a mean correlation coefficient of -0.994 and is linear up to 16.0 g/l. The average coefficients of Variation between and within the runs are 3.6% and 3.5% respectively. The assay has a recovery of 101.4% and 98.9% at low and high levels of digoxin excretion respectively. Dihydrodigoxin at concentrations of 4, 8 and 16 g/l has relative cross reactivities of 12.0%, 7.7% and 4.8% respectively. The assay was applied to compare within-patient and between-patient variability during treatments with Lanoxin® and Lanoxicaps® at steady-state. Precision, sensitivity, broad ränge linearity, convenience of commercially available reagents, insignificant cross reactivity of dihydrodigoxin with the digoxin antibody complex and urinary digoxin excretory data at different dilutions validate our assay for routine monitoring of urinary digoxin. 
n ro ue modify a commercially available radioimmunoassay Research work involving cardioglycosides has been kit to develop a simple and convenient method that limited to some extent by scarcity of Information was usable for urine samples. In addition we checked about radioimmunoassays for digoxin in human the relative cross reactivity of dihydrodigoxin with urine (1-5). The present work was undertaken to the digoxin antibody complex used in the assay.
Methods and Materials

Reagents
Assay buffer
Monosodium phosphate monohydrate (i.84g), disodium phosphatc (3.78 g) and sodium azide (1.0 g) were dissolved in 600 ml of deionized water. 5.0g of bovine serum albumin (RIA-grade, Fraction V, Sigma Chemical Company, P.O. Box 14508» St. Louis, MO 63178) was added with constant stirring. The solution was adjusted to pH 7.4 at room temperature with 10 mol/1 NaOH and then diluted with deionized water to 1.01 in a Volumetrie flask.
serum, and they were processed in the same way s Standards except antiserum addition was repiaced by the same volume of blank antiserum. The urine controls and recovery samples were diluted before analysis so that their concentration feil in the middle portion of the calibration curve. The concentrati n in the samples was calculated using log-log transformation and then multiplying with the dilution factor of the sample. { , Dihydrodigoxin spiked samples were run in the same way s Standards and controls. The apparent digoxin concentration for dihydrodigoxin was calculated using the same log-log transformation and digoxin calibration curve.
Digoxin stock solution
Crystalline digoxin (10mg, No. C037, Burroughs Wellcome Company, Research Triangle Park, NC 27709) was weighed out to the hundreth of a milligram and dissolved in 250 ml of ethanol/ water (80 + 20 by volume). The first ten fold dilution in ethanol/ water (20 + 80 by volume) was followed with another ten fold dilution in assay buffer to produce a digoxin stock solution of 0.4 mg/1.
Urine stock, Standards and controls
Digoxin stock solution (10 ml) was made up to 50 ml with digoxin-free normal human urine to produce a urine stock of 80 μg/l concentration. 
Assay procedure
The RIA was done by pipetting duplicate 0.1 ml aliquots of each Standard into 12 x 75 mm borosilicate glass tubes containing 0.1 ml digoxin-free normal human serum. This was followed with the addition of 0.5 ml of 125 I-labelled digoxin into each tube, and the mixture was vortexed. As soon s tracer ( 125 I-labelled digoxin) was added, each tube was mixed with 0.5 ml of antiserum complex and incubated for 30 min at room temperature. Subsequently, the tubes were centrifuged at 1674 £ for 10 min, decanted and counted for radioactivity in a gamma scintillation counter (Model Searle 1185, Tracor Analytical Inc., 1842 Brummel Drive, Elk Grove Village, IL 60007).
The duplicate set of nonspecific binding tubes was prepared by pipetting 0.1 ml of urine zero Standard into 12 x 75 mm borosilicate glass tubes containing 0.1 ml of digoxin-free normal human
Results and Discussion
Table l summarizes the assay data for severiteen urinary digoxin assays. The calibration curve has a mean correlation coefficient of -0.994 + 0.0025 using log-log transformation. The curve is linear up to 16.0 μg/l when plotted on a logit-log graph ( fig. 1 ). Data in table l and figure l suggest good reproducibility, resolution and linearity over a broad r nge.
The intra-assay Variation determined using ten replicates at low (16 μg/l), mid (40 μ|/1) and high (80 μg/l) concentrations is shown in The present assay is linear up to 16.0 g/l in contrast to linearity up to 6.3 g/l öf a recently reported radioirnmunoassay for urinary digoxin measurement (4). As urinary digoxin levels are always much higher and more variable than plasma digoxin levels, it is usually necessary to analyze multiple dilutions of each sample. The broad ränge linearity of our calibration curve obviates this need.
Dihydrödigoxin is the major cardio-inactive metabolite of digoxin found in measurable quantity in human plasma (6) , and urine (7) . Its cross reactivity with commercially available digoxin RIA kits can vary äs much äs 30% (8) (9) . This may be due to the difference in antibody titer, method of attaching radiolabel to digoxin or digoxin derivative, or Separation techniques employed in the kit for bound and free antigen (8) (9) (10) . A high degree of dihydrödigox-in) cross reactivity with digoxin antibody will not only give false plasma digoxin levels, but will also affect bioavailability data based on urinary measurements (11). The relative cross reactivity for dihydrodigoxin of up to 12.0% in the present assay will produce insignificant change in urinary digoxin measurements.
The present assay was used to compare within-patient and between-patient variability for cumulative digoxin excretion during treatments with Lanoxin® (digoxin in tablet) and Lanoxicaps® (digoxin solution in capsule) in patients in whom steady state serum concentrations were in the therapeutic ränge (0.8-2.0 g/l). These treatments were compared in a multiple dose, cross-over design study in 29 adult patients who required digoxin.
Every patient was studied for two treatment periods each lasting four weeks. The patients consumed their daily dose of Lanoxin® tablets or Lanoxicaps® äs a single dose at 9:30 a. m. (after breakfast). Four urine samples, one each during the 3rd, 4th, 7th and 8th week of the study period in each patient, were collected and analyzed for 24 hour cumulative digoxin excretion. Each urine collection started when the last maintenance dose was administered and terminated 24 hours later. Table 5 documents 24 hour cumulative digoxin excretion during the 3rd, 4th, 7th and 8th week of the study period in two representative patients.
Thus, the precision, broad-range linearity, availability of commercially available reagents, insignificant • r dihydrodigoxin cross-reactivity with digoxin antibody complex, and urinary digoxin excretory data at different dilutions under normal clinical conditions pfovide an excellent basis for the use of our assay for routine urinary digoxin measurements.
